Alnylam's Strong Q4 2024 Earnings: A Catalyst for Future Growth

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported its fourth quarter and full-year 2024 financial results, showcasing robust growth and strategic advancements that position the company for long-term success in the biotech sector. The company's strong performance, driven by its TTR and Rare franchises, highlights its commitment to developing innovative treatments for rare diseases and expanding its therapeutic portfolio.



TTR and Rare Franchise Growth

Alnylam's TTR franchise, comprising ONPATTRO® (patisiran) and AMVUTTRA® (vutrisiran), generated global net product revenues of $343 million in the fourth quarter of 2024, representing a 35% growth compared to Q4 2023. Full-year 2024 revenues for the TTR franchise totaled $1,223 million, reflecting a 34% increase compared to full-year 2023. The Rare franchise, consisting of GIVLAARI® (givosiran) and OXLUMO® (lumasiran), contributed $108 million in the fourth quarter and $423 million for the full year, representing 18% and 29% growth, respectively, compared to the same periods in 2023.

Strategic Advancements and Pipeline Progress

Alnylam's strategic initiatives and pipeline progress further solidify its position in the biotech sector. The company submitted a supplemental New Drug Application (sNDA) for vutrisiran, an RNAi therapeutic for the treatment of ATTR amyloidosis with cardiomyopathy, using a Priority Review Voucher. The FDA accepted the sNDA, setting an action goal date of March 23, 2025, under the Prescription Drug User Fee Act (PDUFA). Additionally, Alnylam received FDA Orphan Drug Designation for nucresiran (ALN-TTRsc04) and plans to initiate a Phase 3 study of nucresiran in patients with ATTR amyloidosis with cardiomyopathy in the first half of 2025.



Alnylam's pipeline also includes promising candidates for Alzheimer's disease and Huntington's disease. The company announced positive initial results from the multiple dose portion of the Phase 1 study of mivelsiran in patients with Alzheimer's disease. Mivelsiran is an RNAi therapeutic targeting TTR, which has shown potential in reducing amyloid-beta plaques in the brain. Furthermore, Alnylam initiated a Phase 1 study of ALN-HTT02 in adult patients with Huntington's disease, targeting the root cause of the progressive brain disorder.

Future Growth Prospects

Alnylam's strong Q4 2024 earnings and strategic advancements position the company for long-term success in the biotech sector. The company's commitment to developing innovative treatments for rare diseases, coupled with its expanding therapeutic portfolio, sets the stage for continued growth and market leadership. As Alnylam awaits the FDA's PDUFA decision on vutrisiran, investors should closely monitor the company's progress and consider the potential benefits and risks associated with its strategic initiatives and pipeline advancements.

In conclusion, Alnylam Pharmaceuticals' strong Q4 2024 earnings and strategic advancements highlight the company's commitment to developing innovative treatments for rare diseases and expanding its therapeutic portfolio. With a robust pipeline and a focus on long-term growth, Alnylam is well-positioned to capitalize on emerging opportunities in the biotech sector. Investors should closely monitor the company's progress and consider the potential benefits and risks associated with its strategic initiatives and pipeline advancements.